Thanks for emailing that article!
San Francisco, CA - January 12, 2016: Glaucoma Research Foundation will host the fifth annual Glaucoma 360 New Horizons Forum on January 29, 2016 at the historic Palace Hotel in San Francisco.
This unique meeting brings clinicians together with key leaders in industry, business, finance and the FDA to highlight and advance promising developments in glaucoma treatment. Glaucoma is the leading global cause of irreversible blindness and the number of cases is expected to reach 80 million by 2030 as the population ages.
Co-founded by Adrienne L. Graves, PhD, a member of the Glaucoma Research Foundation board and Andrew G. Iwach, MD, director of the Glaucoma Center of San Francisco and chairman of the Foundation’s board, the goal of the meeting is to highlight innovations in glaucoma and unite the various elements needed to bring a new idea into clinical use.
“Over the past four years, the New Horizons Forum has provided a unique venue to get everyone in the glaucoma space together to stimulate and facilitate key discussions and connections. It's a unique way the Glaucoma Research Foundation serves as a catalyst in the development of new glaucoma therapies that will help patients preserve their vision” said Dr. Graves.
Dr. Iwach added “At New Horizons we have numerous companies presenting their new technologies and approaches to glaucoma care. At the same time, we have venture capitalists looking for their next investment opportunities, and the FDA is here to provide useful tools and advice to the innovators to help them take these new ideas into practice. Each year there have been significant new developments and we are anxious to learn more details at our 2016 meeting.”
Richard A. Lewis, MD, Co-founder of the Sacramento Eye Consultants and Former Director of Glaucoma at the University of California, Davis will deliver the Drs. Henry and Frederick Sutro Memorial Lecture. The keynote lecture starts a full day of presentations and industry panel discussions featuring new innovations in glaucoma drug delivery, pharmaceuticals, devices and vision restoration as well as sessions focusing on working with the FDA and securing venture capital funding.
Additional invited speakers include David E.I. Pyott, CBE, former Chairman of the Board and Chief Executive Officer of Allergan, Inc.; Larry Benowitz, PhD, Boston Children’s Hospital and Harvard Medical School; Kapil Bharti, PhD, National Eye Institute; and Bernhard Sabel, PhD, Otto-van-Guericke University of Magdeburg. Attendees and other program participants include nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA.
Presenting companies featured include Aerie Pharmaceuticals, Inc.; Bausch + Lomb; Envisia Therapeutics; EBS Technologies GmbH; Equinox LLC; ForSight VISION5; Glaukos Corporation; GrayBug; InnFocus, Inc.; Inotek Pharmaceuticals; Ivantis; MicroOptx; Neurotech Pharmaceuticals, Inc.; New World Medical; Ocata Therapeutics; Ocular Therapeutix, Inc.; Ohr Pharmaceuticals; Sanoculis; and Transcend Medical.
The New Horizons Forum is the centerpiece of Glaucoma 360, Glaucoma Research Foundation’s signature three-day event, which includes a fundraising Gala honoring longtime Atherton, CA residents, Charlot and Dennis Singleton, laser innovator James Wise, MD, and Union Bank’s Masashi Oka. Glaucoma 360 closes with the 20th Annual Glaucoma Symposium, the largest glaucoma medical education meeting in North America.
All proceeds from Glaucoma 360 support Glaucoma Research Foundation’s research and education programs. To learn more about the January 28 - 30th event at San Francisco’s historic Palace Hotel, and to register, visit: www.glaucoma360.org.
Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $50 million into research and education to prevent vision loss from glaucoma. More information is available at www.glaucoma.org. Contact: Andrew Jackson, Director of Communications, phone (415) 986-3162.
Last reviewed on January 12, 2016